Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 12/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.40 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29399296 | 0.78 | CA1 (0.44) | CA1CA2CA12CA9PTGS2 | |
| SCHEMBL24266208 | 0.78 | CA1 (0.44) | CA1CA2CA12CA9PTGS2 | |
| SCHEMBL31578554 | 0.77 | CA1 (0.49) | CA1CA2CA12CA9PTGS2 | |
| SCHEMBL25365631 | 0.77 | CA1 (0.49) | CA1CA2CA12CA9PTGS2 | |
| SCHEMBL25365002 | 0.76 | PLAT (0.44) | CA1CA2CA12CA9PTGS2 | |
| SCHEMBL30899903 | 0.76 | HSD11B1 (0.49) | CA1CA2CA12CA9PTGS2 | |
| SCHEMBL30899910 | 0.76 | HSD11B1 (0.49) | CA1CA2CA12CA9PTGS2 | |
| SCHEMBL26119405 | 0.75 | PTGS2 (0.43) | PTGS2PTGS1HSD17B10 | |
| SCHEMBL25363887 | 0.74 | MAP4K1 (0.52) | PTGS2PTGS1 | |
| SCHEMBL25365465 | 0.74 | GPR119 (0.40) | CA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177363-A1 | SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-06-05 | — | — | US | disclosed |
| EP-4479135-A1 | SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | Bristol-Myers Squibb Company (US) | 2024-12-25 | — | — | EP | disclosed |
| WO-2023159154-A9 | SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-10-10 | — | — | WO | disclosed |
| WO-2023159154-A1 | SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250177363-A1 | SUBSTITUTED IMIDAZOPYRIDINYL COMPOUNDS USEFUL AS INHIBITORS OF TLR9 | TLR9, TLR3, TLR1 | CA1 4646/4885CA2 2230/4885CA12 4775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.